Ketamine Continuous Infusion for Refractory Status Epilepticus in a Patient With Anticonvulsant Hypersensitivity Syndrome

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1569-1576

  Esaian, Diana ^a   Joset, Danielle ^a   Lazarovits, Candace ^a   Dugan, Patricia C ^a   Fridman, David ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticonvulsant hypersensitivity reaction; ketamine; pentobarbital; refractory status epilepticus

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; AMPICILLIN; ANTICONVULSIVE AGENT; COTRIMOXAZOLE; ETIRACETAM; HARKOSERIDE; IMMUNOGLOBULIN; KETAMINE; METHYLPREDNISOLONE; MIDAZOLAM; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; TOPIRAMATE; VALPROIC ACID; VASOPRESSIN;

ADD ON THERAPY; ADULT; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; CONTROL; DIABETES INSIPIDUS; DRESS SYNDROME; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; HOSPITAL; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; LIVER TOXICITY; LOADING DRUG DOSE; PRIORITY JOURNAL; SEIZURE; SWELLING; WEANING;

ANTICONVULSANT HYPERSENSITIVITY REACTION; KETAMINE; PENTOBARBITAL; REFRACTORY STATUS EPILEPTICUS;

ADULT; ANTICONVULSANTS; DRUG HYPERSENSITIVITY SYNDROME; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MIDAZOLAM; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84889014770     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013505427     Document Type: Article

References (38)

1. Lowenstein DH,Bleck T,Macdonald RL.It's time to revise the definition of status epilepticus.Epilepsia. 1999;40:120-122.
2. Marik PE,Varon J.The management of status epilepticus.Chest. 2004;126:582-591.
3. Fernandez A,Claassen J.Refractory status epilepticus.Curr Opin Crit Care. 2012;18:127-131.
4. Tesoro EP,Brophy GM.Pharmacological management of seizures and status epilepticus in critically ill patients.J Pharm Pract. 2010;23:441-454.
5. Borris DJ,Bertram EH,Kapur J.Ketamine controls prolonged status epilepticus.Epilepsy Res. 2000;42:117-122.
6. Hsieh CY,Sung PS,Tsai JJ,Huang CW.Terminating prolonged refractory status epilepticus using ketamine.Clin Neuropharmacol. 2010;33:165-167.
7. Kramer AH.Early ketamine to treat refractory status epilepticus.Neurocrit Care. 2012;16:299-305.
8. Ubogu EE,Sagar SM,Lerner AJ,Maddux BN,Suarez JI,Werz MA.Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.Epilepsy Behav. 2003;4:70-75.
9. Pruss H,Holtkamp M.Ketamine successfully terminates malignant status epilepticus.Epilepsy Res. 2008;82:219-222.
10. Rossetti AO,Milligan TA,Vulliemoz S,Michaelides C,Bertschi M,Lee JW.A randomized trial for the treatment of refractory status epilepticus.Neurocrit Care. 2011;14:4-10.
11. Claassen J,Hirsch LJ,Emerson RG,Bates JE,Thompson TB,Mayer SA.Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus.Neurology. 2001;57:1036-1042.
12. Mayer SA,Claassen J,Lokin J,Mendelsohn F,Dennis LJ,Fitzsimmons BF.Refractory status epilepticus: frequency, risk factors, and impact on outcome.Arch Neurol. 2002;59:205-210.
13. Brophy GM,Bell R,Claassen J,et al.Guidelines for the evaluation and management of status epilepticus.Neurocrit Care. 2012;17:3-23.
14. Tas S,Simonart T.Management of drug rash with eosinophilia and Systemic Symptoms (DRESS Syndrome): an update.Dermatology. 2003;206:353-356.
15. Krauss G.Current understanding of delayed anticonvulsant hypersensitivity reactions.Epilepsy Curr. 2006;6:33-37.
16. Gennis MA,Vermuri R,Burns EA,Hill JV,Miller MA,Spielberg SP.Familial occurrence of hypersensitivity to phenytoin.Am J Med. 1991;91:631-634.
17. Gaedigk A,Spielberg SP,Grant DM.Characterization of the microsomal epoxide hydroxylase gene in patients with anticonvulsant adverse drug reaction.Pharmacogenetics. 1994;4:142-153.
18. Chung WH,Hung SI,Hong HS,et al.Medical genetics: a marker for Stevens-Johnson syndrome.Nature. 2004;428:486.
19. Lonjou C,Thomas I,Borot N,et al.A marker for Stevens-Johnson syndrome...: ethnicity matters.Pharmacogenomics J. 2006;6:265-268.
20. Knowles SR,Dewhurst N,Shear NH.Anticonvulsant hypersensitivity syndrome: an update.Expert Opin Drug Saf. 2012;11:767-778.
21. Bohan KB,Mansuri TF,Wilson NM.Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care.Pharmacotherapy. 2007;27:1425-1439.
22. Knowles SR,Shapiro LE,Shear NH.Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.Drug Saf. 1999;21:489-501.
23. Mostella J,Pieroni R,Jones R,Finch CK.Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin.South Med J. 2004;97:319-322.
24. Straussberg R,Harel L,Ben-Amitai D,Cohen D,Amir J.Carbamazepine-induced Stevens-Johnson syndrome treated with IV steroids and IVIG.Pediatr Neurol. 2000;22:231-233.
25. Prais D,Straussberg R,Amir J,Nussinovitch M,Harel L.Treatment of anticonvulsant hypersensitivity syndrome with intravenous immunoglobulins and corticosteroids.J Child Neurol. 2006;21:380-384.
26. Dredge DC,Parsons EC,Carter LP,Staley KJ.Anticonvulsants hypersensitivity syndrome treated with intravenous immunoglobulin.Pediatr Neurol. 2010;43:65-69.
27. Redondo P,de Felipe I,de la Pena A,Aramendia JM,Vanaclocha V.Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with N-acetylcysteine.Br J Dermatol. 1997;136:645-646.
28. Simonart T,Tugendhaft P,Vereecken P,De Dobbeleer G,Heenen M.Hazards of therapy with high doses of N-acetylcysteine for anticonvulsant-induced hypersensitivity syndrome.Br J Dermatol. 1998;138:553.
29. Tas S,Simonart T,Heenen M.Angio-oedema caused by high doses of N-acetylcysteine in patients with anticonvulsant hypersensitivity syndrome.Br J Dermatol. 2001;145:856-857.
30. Naylor DE,Liu H,Wasterlain CG.Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus.J Neurosci. 2005;25:7724-7733.
31. Chen JW,Wasterlain CG.Status epilepticus: pathophysiology and management in adults.Lancet Neurol. 2006;5:246-256.
32. Ubogu EE,Sagar SM,Lerner AJ,Maddux BN,Suarez JI,Werz MA.Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.Epilepsy Behav. 2003;4:70-75.
33. Pruss H,Holtkamp M.Ketamine successfully terminates malignant status epilepticus.Epilepsy Res. 2008;82:219-222.
34. Hsieh CY,Sung PS,Tsai JJ,Huang CW.Terminating prolonged refractory status epilepticus using ketamine.Clin Neuropharmacol. 2010;33:165-167.
35. Yeh PS,Shen HN,Chen TY.Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient.Seizure. 2011;20:723-726.
36. Kramer AH.Early Ketamine to treat refractory status epilepticus.Neurocrit Care. 2012;16:299-305.
37. Borris DJ,Bertram EH,Kapur J.Ketamine controls prolonged status epilepticus.Epilepsy Res. 2000;42:117-122.
38. Rossetti AO,Lowenstein DH.Management of refractory status epilepticus in adults: still more questions than answers.Lancet Neurol. 2011;10:922-930.